Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 22, 2011Tue, June 21, 2011Mon, June 20, 2011Sun, June 19, 2011Fri, June 17, 2011Thu, June 16, 2011Wed, June 15, 2011Tue, June 14, 2011Mon, June 13, 2011Fri, June 10, 2011Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Sat, June 4, 2011Fri, June 3, 2011Thu, June 2, 2011Wed, June 1, 2011Tue, May 31, 2011Mon, May 30, 2011Fri, May 27, 2011Thu, May 26, 2011Wed, May 25, 2011ARIAD to Host Analyst & Investor Day in New York City
Published in Health and Fitness on Friday, June 10th 2011 at 4:46 GMT by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIADa™s continued progress in its research and development programs and near-term commercial plans. Expert medical leaders in the fields of sarcomas, chronic myeloid leukemia and lung cancer will be featured speakers and discussants at the meeting.
A live webcast of the Analyst & Investor Day can be accessed by visiting the investor relations section of ARIADa™s website at [ http://www.ariad.com/investor ].
About ARIAD
ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIADa™s product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck that has successfully completed a Phase 3 clinical trial in patients with soft-tissue and bone sarcomas and is being studied in multiple cancer indications. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information, please visit [ http://www.ariad.com ].
